Oncolytic Virus Therapy Market - Strategic Insights and Forecasts (2026-2031)

The Oncolytic Virus Therapy Market is projected to reach an impressive USD 1,123.60 billion by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 30.8%. This significant expansion is anticipated from a market size of USD 293.3 billion in 2026, reflecting the rapid evolution and adoption of these innovative cancer treatments.

The market's substantial growth is primarily driven by the 'Rising Global Cancer Burden,' which necessitates more effective and targeted treatment options beyond conventional therapies. Additionally, 'Advancements in Genetic Engineering Technologies' have significantly enhanced the efficacy, safety, and tumor-targeting capabilities of oncolytic viruses, making them increasingly viable clinically.

Oncolytic virus therapies offer a dual mechanism by preferentially infecting and killing cancer cells while simultaneously stimulating systemic anti-tumor immune responses. This positions them as a promising alternative, particularly when tumors exhibit resistance to conventional treatments like chemotherapy or radiotherapy, thereby offering improved outcomes for difficult-to-treat cancers.

Key trends include a significant shift toward genetically modified oncolytic viruses that enhance tumor selectivity and immune activation, often incorporating transgenes like cytokines and immune modulators. Furthermore, strategic collaborations between pharmaceutical companies and academic institutions are accelerating innovation, alongside the integration of oncolytic viruses with existing immunotherapies to improve response rates.

The report highlights Elicera Therapeutics AB (publ), a clinical-stage cell and gene therapy company, which is developing next-generation cancer therapies based on its proprietary iTANK platform. The company has released final results from its Phase I/IIa clinical trial, showcasing advancements in this evolving competitive landscape.

Tumor heterogeneity is a key challenge limiting the universal efficacy of oncolytic virus therapies, as varied cancer cell populations can reduce treatment effectiveness. The market is actively responding to this by pushing demand toward personalized viral engineering approaches, aiming to tailor therapies for specific cancer types and individual tumor characteristics to improve outcomes.